![](/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBHQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--e623d2450603cd9d4e6c86eae39da2c5b7f7bdd9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdERG9MY21WemFYcGxTU0lOTXpJd2VERTRNRjRHT2daRlZEb0pZM0p2Y0VraUVETXlNSGd4T0RBck1Dc3dCanNHVkRvTVozSmhkbWwwZVVraUMyTmxiblJsY2dZN0JsUTZESEYxWVd4cGRIbHBWVG9LYzNSeWFYQlVPZzVwYm5SbGNteGhZMlZKSWdsTWFXNWxCanNHVkRvTFpHVm1hVzVsU1NJZWFuQmxaenBtWVc1amVTMTFjSE5oYlhCc2FXNW5QVzltWmdZN0JsUT0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--daee5f4cd191d67586af9b48495fbde7d4763d64/lucas-vasques-453684-unsplash.jpg)
Partner News & Updates
-
Acquisition significantly expands Janssen’s eye disease portfolio and strengthens its gene therapy capabilities. Late-stage AMD affects millions of people with no effective treatments currently available .
-
Abfero Targeting Excess Iron to Treat AMD, Other Retinal Diseases
An intriguing link between excess body iron and retinal degeneration is being explored by Abfero Pharmaceuticals, a young biotech based in Boston and Oxford, UK.